In cancer patients, it has been demonstrated that upon anti-CTLA-4 treatment, the number of circulating Th17 cells in patients increases, especially in those patients who developed clinically relevant inflammatory and autoimmune toxicities (56). Here, CTLA4 is linked to cancer.